Benelux
Ovizio raises €8m from NSV et al.
VC's second foray in Belgian healthcare in recent months
PGGM backs private equity regulation drive in Netherlands
Pension fund welcomes Labour's greater transparency proposal
Arsenal Capital's IGM completes refinancing
Transaction features €25m unitranche from HIG WhiteHorse
Kebek to buy majority stake in Cardoen
Maiden deal for GP’s €50m second fund
Idinvest et al. in $10.2m series-B for Ngdata
Round comes two years after $3.3m series-A
Benelux Q3 dealflow remains subdued but value rockets
Dealflow remained subdued in Q3 but value soared thanks to handful of larger deals
Gimv injects €12.5m into Zorgbedrijven
GP to secure minority stake in clinic operator
PE-backed $3.3bn Lumileds carve-out delayed by US regulators
CFIUS expresses "unforeseen concerns" around the takeover
H2 offloads Isero to Grafton
H2 first invested in Isero in 2010
Parcom et al. acquire Imtech Marine
Latest subsidiary to be sold by troubled parent Imtech
Deal in Focus: Main Capital boosts software drive with Ymor
The buyout of Ymor highlights Main Capital's build-up approach to the Benelux software segment
BC Partners buys Dümmen Orange
BC Partners has acquired Dutch flower business Dümmen Orange in a secondary buyout from H2 Equity Partners.
Comment: Luxembourg a hub for VC platforms
Its efficient tax environment and economic and political stability make Luxembourg ideal for VCs
Argos Soditic acquires Gantrex
Deal sees Argos make its second foray in Belgian market
Curetis eyes IPO on Euronext
Company was founded in 2007
Main's Roxit to merge with Green Valley
First move in build-up strategy since July buyout
Monitor's STS bolts on MSS
Acquisition of sixth unit follows Luigi Salvadori add-on in May
SFPI-FPIM et al. in €16m series-B for Euroscreen
Drug developer has received €28m in funding since 2012
Vendis bolsters French operations with two hires
De Pimodan and Snijders appointed director and analyst at Paris office
Main buys majority stake in Ymor
GP recently closed €85m fourth fund
Deal in Focus: Forbion to reap 50x on $1.55bn Dezima sale
Sale of Dezima could result in a staggering 50x return for Forbion
Navigating privatisation opportunities in Belgium
Privatisation opportunities could shake up this quiet market
Forbion's Dezima sold to Amgen
VC exits two years after backing the company's creation
Initial Capital in $1.9m round for BUX
Business to target growth in additional European markets